|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's range||1.3000 - 1.3000|
|52-week range||1.0692 - 3.0000|
|Beta (5Y monthly)||-0.10|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Tiziana (TLSA) reports positive data from a study investigating its anti-CD3 human monoclonal antibody, foralumab (nasally administered) for treating COVID-19 patients in Brazil. Shares up.
The big shareholder groups in Tiziana Life Sciences PLC ( LON:TILS ) have power over the company. Institutions often...
As of late, it has definitely been a great time to be an investor in Tiziana Life Sciences (TLSA).